Adlai Nortye (NASDAQ:ANL) Stock Price Up 3.2% – Should You Buy?

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) rose 3.2% during mid-day trading on Monday . The stock traded as high as $1.68 and last traded at $1.61. Approximately 1,460 shares were traded during trading, a decline of 78% from the average daily volume of 6,538 shares. The stock had previously closed at $1.56.

Analysts Set New Price Targets

Separately, HC Wainwright lowered shares of Adlai Nortye from a “buy” rating to a “neutral” rating in a research report on Monday, June 2nd.

Adlai Nortye Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.41 and a current ratio of 1.41. The firm has a 50-day moving average of $1.54 and a 200-day moving average of $1.88.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.